Is Raloxifene Hydrochloride Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Raloxifene Hydrochloride? Is Raloxifene Hydrochloride safe for nursing mother and child? Does Raloxifene Hydrochloride extracts into breast milk? Does Raloxifene Hydrochloride has any long term or short term side effects on infants? Can Raloxifene Hydrochloride influence milk supply or can Raloxifene Hydrochloride decrease milk supply in lactating mothers?

• DrLact safety Score for Raloxifene Hydrochloride is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Raloxifene Hydrochloride may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Raloxifene Hydrochloride may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Raloxifene Hydrochloride .
• It is recommended to evaluate the advantage of not breastfeeding while using Raloxifene Hydrochloride Vs not using Raloxifene Hydrochloride And continue breastfeeding.
• While using Raloxifene Hydrochloride Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Selective estrogen receptor modulator. Estrogen agonist in bone and estrogen receptor antagonist in breast and uterine tissue.Indicated in treating osteoporosis and preventing breast cancer. Raloxifene does not alter prolactin secretion in premenopausal women but increases levels of estradiol and sex-hormone binding globulin (BGSH). At last update no published data on excretion in breast milk were found.Pharmacokinetic data (large volume of distribution, moderately high molecular weight and high percentage of protein binding) make it unlikely milk passage of significant amounts.Low oral bioavailability hinders the passage into infant plasma from ingested milk except in preterm neonates and immediate neonatal period, because an increased intestinal permeability can appear. Although short-term treatments may be of low risk during breastfeeding, the anti-estrogenic effect on breast tissue, a prolonged use is not recommended.